Plasminogen Activator Inhibitor 1

• 

  Subject Areas on Research

  • A novel mechanism for regulating transforming growth factor beta (TGF-beta) signaling. Functional modulation of type III TGF-beta receptor expression through interaction with the PDZ domain protein, GIPC. 
  • A prospective longitudinal multicenter study of coagulation in pediatric patients undergoing allogeneic stem cell transplantation. 
  • Additional impact of morning haemostatic risk factors and morning blood pressure surge on stroke risk in older Japanese hypertensive patients. 
  • An association between the 4G polymorphism in the PAI-1 promoter and the development of aggressive fibromatosis (desmoid tumor) in familial adenomatous polyposis patients. 
  • Anti-angiogenic effects of interleukin-12 delivered by a novel hyperthermia induced gene construct. 
  • Antimetastatic potential of PAI-1-specific RNA aptamers. 
  • Association of sleep onset of acute coronary syndrome with sleep apnea syndrome and abnormal diurnal variation of hemostasis and adipokine levels. 
  • Causal Effect of Plasminogen Activator Inhibitor Type 1 on Coronary Heart Disease. 
  • Circulating des-acyl ghrelin improves cardiovascular risk prediction in older hypertensive patients. 
  • Construct validity of the definition of primary graft dysfunction after lung transplantation. 
  • Cross-sectional relations of multiple biomarkers representing distinct biological pathways to plasma markers of collagen metabolism in the community. 
  • Decreased fibrinolytic activity in porcine-to-primate cardiac xenotransplantation. 
  • Effects of plasminogen activator inhibitor-1-specific RNA aptamers on cell adhesion, motility, and tube formation. 
  • Enhanced Thrombin Formation in Patients With Ventricular Assist Devices Experiencing Bleeding: Insights From the Multicenter PREVENT Study. 
  • Evidence for preferential adhesion of ovarian epithelial carcinoma cells to type I collagen mediated by the alpha2beta1 integrin. 
  • Fibrinolytic abnormalities in two different cutaneous manifestations of venous disease. 
  • Genome-wide association study for circulating levels of PAI-1 provides novel insights into its regulation. 
  • Heparin-associated anti-Xa activity and platelet-derived prothrombotic and proinflammatory biomarkers in moderate to high-risk patients with acute coronary syndrome. 
  • IGF1R as a Key Target in High Risk, Metastatic Medulloblastoma. 
  • Multimarker approach to evaluate the incidence of the metabolic syndrome and longitudinal changes in metabolic risk factors: the Framingham Offspring Study. 
  • Ozone exposure is associated with acute changes in inflammation, fibrinolysis, and endothelial cell function in coronary artery disease patients. 
  • PRDX6 attenuates oxidative stress- and TGFbeta-induced abnormalities of human trabecular meshwork cells. 
  • Pathogenetic and prognostic significance of altered coagulation and fibrinolysis in acute lung injury/acute respiratory distress syndrome. 
  • Plasma des-acyl ghrelin, but not plasma HMW adiponectin, is a useful cardiometabolic marker for predicting atherosclerosis in elderly hypertensive patients. 
  • Plasminogen activator inhibitor-1 (PAI-1) activity and retinal vascular calibre in type 2 diabetes. 
  • Plasminogen activator inhibitor-1 (PAI-1) modifies the formation of aggressive fibromatosis (desmoid tumor). 
  • Polymorphism of angiotensin converting enzyme gene is associated with circulating levels of plasminogen activator inhibitor-1. 
  • Protein Quantitative Trait Loci Analysis Identifies Genetic Variation in the Innate Immune Regulator TOLLIP in Post-Lung Transplant Primary Graft Dysfunction Risk. 
  • RNA interference targeting hypoxia inducible factor 1α reduces post-operative adhesions in rats 
  • Regulation of fibrinolysis by platelet-released plasminogen activator inhibitor 1: light scattering and ultrastructural examination of lysis of a model platelet-fibrin thrombus. 
  • Short-term high-dose effect of lovastatin on thrombolysis by rt-PA in a human whole-blood in vitro clot model. 
  • Skeletal muscle dictates the fibrinolytic state after exercise training in overweight men with characteristics of metabolic syndrome. 
  • Skin abnormalities in mice transgenic for plasminogen activator inhibitor 1: implications for the regulation of desquamation and follicular neogenesis by plasminogen activator enzymes. 
  • Specific binding of urinary-type plasminogen activator (u-PA) to vitronectin and its role in mediating u-PA-dependent adhesion of U937 cells. 
  • Suppression of Fibrinolysis and Hypercoagulability, Severity of Hypoxemia, and Mortality in COVID-19 Patients: A Retrospective Cohort Study. 
  • Targeted disruption of Smad3 reveals an essential role in transforming growth factor beta-mediated signal transduction. 
  • The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. 
  • The effects of intermittent pneumatic compression during cesarean delivery on fibrinolysis. 
  • The human plasminogen activator inhibitor type I gene promoter targets to kidney. 
  • The impact of angiotensin II receptor blockade and the DASH diet on markers of endogenous fibrinolysis. 
  • The impact of cigarette smoking on 24-hour blood pressure, inflammatory and hemostatic activity, and cardiovascular risk in Japanese hypertensive patients. 
  • The influence of abdominal visceral fat on inflammatory pathways and mortality risk in obstructive lung disease. 
  • Thromboxane A2modulates the fibrinolytic system in glomerular mesangial cells. 
  • Tumor suppressor Smad4 is a transforming growth factor beta-inducible DNA binding protein. 
  • Vascular regulation of plasminogen activator inhibitor-1 activity.